

Figure S1. KDM5B expression in neuroblastoma MYCN amplifies cell line UKF-NB-3. (A) Treatment with 20  $\mu$ M CDDP for 48 h did not modulate KDM5B level in both cell lines. \* $P < 0.05$  and \*\*\* $P < 0.001$  compared with NB3. (B) Expression of KDM5B protein detected by western blotting in UKF-NB-3 (NB3) and CDDP resistant UKF-NB-3<sup>CDDP</sup> (NB3CD) cell lines. (C) Representative bar chart of the western blotting results shown. KDM5B, lysine-specific demethylase 5B; CDDP, cisplatin.




Figure S2. KDM5B expression in neuroblastoma cell line without MYCN amplification SK-N-AS. Expression of KDM5B mRNA and protein detected by (A) Reverse transcription-quantitative PCR and (B) western blotting in SK-N-AS (SK) and CDDP resistant SK-N-AS<sup>CDDP</sup> (SKCD) cell lines. (C) Representative bar chart of western blotting. \*P<0.05 compared with SK group. KDM5B, lysine-specific demethylase 5B; CDDP, cisplatin.

